Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B

Eugene R Schiff, Samuel S. Lee, You Chen Chao, Seung Kew Yoon, Fernando Bessone, Shun Sheng Wu, Wieslaw Kryczka, Yoav Lurie, Adrian Gadano, George Kitis, Suzanne Beebe, Dong Xu, Hong Tang, Uchenna Iloeje

Research output: Contribution to journalArticle

110 Citations (Scopus)

Abstract

Background & Aims: Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. Patients with advanced fibrosis or cirrhosis, who received long-term entecavir treatment, were evaluated for improvement in liver histology. Methods: The study included a subset of patients from phase III and long-term rollover studies, who received entecavir for at least 3 years, had advanced fibrosis or cirrhosis, and evaluable biopsies at baseline and after long-term treatment. Results: Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score, ≥4). After approximately 6 years of cumulative entecavir therapy (range, 267-297 wk), all 10 patients showed improvement in liver histology and Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and Knodell necroinflammatory scores were -2.2 and -7.6, respectively. A reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients who had cirrhosis at baseline. Conclusions: Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated histologic improvement and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.

Original languageEnglish
JournalClinical Gastroenterology and Hepatology
Volume9
Issue number3
DOIs
StatePublished - Mar 1 2011

Fingerprint

Chronic Hepatitis B
Fibrosis
Therapeutics
entecavir
Histology
Liver
Nucleosides

Keywords

  • Biopsy
  • Entecavir
  • Histologic Improvement
  • Ishak Fibrosis Score

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B. / Schiff, Eugene R; Lee, Samuel S.; Chao, You Chen; Kew Yoon, Seung; Bessone, Fernando; Wu, Shun Sheng; Kryczka, Wieslaw; Lurie, Yoav; Gadano, Adrian; Kitis, George; Beebe, Suzanne; Xu, Dong; Tang, Hong; Iloeje, Uchenna.

In: Clinical Gastroenterology and Hepatology, Vol. 9, No. 3, 01.03.2011.

Research output: Contribution to journalArticle

Schiff, ER, Lee, SS, Chao, YC, Kew Yoon, S, Bessone, F, Wu, SS, Kryczka, W, Lurie, Y, Gadano, A, Kitis, G, Beebe, S, Xu, D, Tang, H & Iloeje, U 2011, 'Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B', Clinical Gastroenterology and Hepatology, vol. 9, no. 3. https://doi.org/10.1016/j.cgh.2010.11.040
Schiff, Eugene R ; Lee, Samuel S. ; Chao, You Chen ; Kew Yoon, Seung ; Bessone, Fernando ; Wu, Shun Sheng ; Kryczka, Wieslaw ; Lurie, Yoav ; Gadano, Adrian ; Kitis, George ; Beebe, Suzanne ; Xu, Dong ; Tang, Hong ; Iloeje, Uchenna. / Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B. In: Clinical Gastroenterology and Hepatology. 2011 ; Vol. 9, No. 3.
@article{2f0896ab6ae74641acc7f297b610d4fe,
title = "Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B",
abstract = "Background & Aims: Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. Patients with advanced fibrosis or cirrhosis, who received long-term entecavir treatment, were evaluated for improvement in liver histology. Methods: The study included a subset of patients from phase III and long-term rollover studies, who received entecavir for at least 3 years, had advanced fibrosis or cirrhosis, and evaluable biopsies at baseline and after long-term treatment. Results: Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score, ≥4). After approximately 6 years of cumulative entecavir therapy (range, 267-297 wk), all 10 patients showed improvement in liver histology and Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and Knodell necroinflammatory scores were -2.2 and -7.6, respectively. A reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients who had cirrhosis at baseline. Conclusions: Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated histologic improvement and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.",
keywords = "Biopsy, Entecavir, Histologic Improvement, Ishak Fibrosis Score",
author = "Schiff, {Eugene R} and Lee, {Samuel S.} and Chao, {You Chen} and {Kew Yoon}, Seung and Fernando Bessone and Wu, {Shun Sheng} and Wieslaw Kryczka and Yoav Lurie and Adrian Gadano and George Kitis and Suzanne Beebe and Dong Xu and Hong Tang and Uchenna Iloeje",
year = "2011",
month = "3",
day = "1",
doi = "10.1016/j.cgh.2010.11.040",
language = "English",
volume = "9",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B

AU - Schiff, Eugene R

AU - Lee, Samuel S.

AU - Chao, You Chen

AU - Kew Yoon, Seung

AU - Bessone, Fernando

AU - Wu, Shun Sheng

AU - Kryczka, Wieslaw

AU - Lurie, Yoav

AU - Gadano, Adrian

AU - Kitis, George

AU - Beebe, Suzanne

AU - Xu, Dong

AU - Tang, Hong

AU - Iloeje, Uchenna

PY - 2011/3/1

Y1 - 2011/3/1

N2 - Background & Aims: Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. Patients with advanced fibrosis or cirrhosis, who received long-term entecavir treatment, were evaluated for improvement in liver histology. Methods: The study included a subset of patients from phase III and long-term rollover studies, who received entecavir for at least 3 years, had advanced fibrosis or cirrhosis, and evaluable biopsies at baseline and after long-term treatment. Results: Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score, ≥4). After approximately 6 years of cumulative entecavir therapy (range, 267-297 wk), all 10 patients showed improvement in liver histology and Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and Knodell necroinflammatory scores were -2.2 and -7.6, respectively. A reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients who had cirrhosis at baseline. Conclusions: Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated histologic improvement and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.

AB - Background & Aims: Long-term treatment with entecavir resulted in durable virologic suppression and continued histologic improvement in nucleoside-naive chronic hepatitis B patients. Patients with advanced fibrosis or cirrhosis, who received long-term entecavir treatment, were evaluated for improvement in liver histology. Methods: The study included a subset of patients from phase III and long-term rollover studies, who received entecavir for at least 3 years, had advanced fibrosis or cirrhosis, and evaluable biopsies at baseline and after long-term treatment. Results: Ten patients had advanced fibrosis or cirrhosis at baseline (Ishak fibrosis score, ≥4). After approximately 6 years of cumulative entecavir therapy (range, 267-297 wk), all 10 patients showed improvement in liver histology and Ishak fibrosis score. The mean change from baseline in Ishak fibrosis and Knodell necroinflammatory scores were -2.2 and -7.6, respectively. A reduction in Ishak fibrosis score to 4 or less was observed for all 4 patients who had cirrhosis at baseline. Conclusions: Chronic hepatitis B patients with advanced fibrosis or cirrhosis demonstrated histologic improvement and reversal of fibrosis and cirrhosis after long-term treatment with entecavir.

KW - Biopsy

KW - Entecavir

KW - Histologic Improvement

KW - Ishak Fibrosis Score

UR - http://www.scopus.com/inward/record.url?scp=79951684909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951684909&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2010.11.040

DO - 10.1016/j.cgh.2010.11.040

M3 - Article

C2 - 21145419

AN - SCOPUS:79951684909

VL - 9

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 3

ER -